文献速递妇科

双靶向抑制GSK3B和HDACs可减少卵巢癌小鼠模型的肿瘤生长并提高生存率

Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
PubMed 文献 · Gynecol Oncol · 2020-07-19

该研究在体外和免疫 competent 同基因小鼠模型中评估了新开发的双重抑制剂APCS-540(靶向糖原合成酶激酶3β和组蛋白去乙酰化酶)的抗肿瘤效果。APCS-540在人和小鼠卵巢癌细胞中显示出显著抗肿瘤作用,对顺铂耐药细胞有细胞毒性,与铂类联用可逆转顺铂耐药,并显著减少癌细胞侵袭。在BR-Luc小鼠模型中,APCS-540组较对照组生存率显著提高66%。

要点

  • APCS-540在体外对人和小鼠卵巢癌细胞显示显著抗肿瘤效果。
  • APCS-540对顺铂耐药癌细胞有细胞毒性,与铂类联用可逆转顺铂耐药。
  • APCS-540组小鼠较对照组生存率显著提高66%。

核心结论

  • 通过APCS-540双重抑制GSK3B和HDACs在体外和体内均显示出强效抗肿瘤活性,提示APCS-540可能为卵巢癌(包括铂耐药疾病)提供新的治疗选择。

研究设计与样本

  • 体外研究使用人卵巢癌细胞(KURAMOCHI、OVCA420、OVSAHO)和小鼠卵巢癌细胞(BR-Luc、ID8、MOSE-HRas-Myc),并使用顺铂敏感(A2780)和顺铂耐药(A2780cis)细胞系评估APCS-540对化疗耐药的影响。
  • 体内研究使用免疫 competent 同基因小鼠模型BR-Luc测试APCS-540对卵巢癌进展和生存的影响。

主要发现

  • APCS-540在体外对人和小鼠卵巢癌细胞均显示出显著抗肿瘤效果。
  • APCS-540对顺铂耐药癌细胞表现出明显细胞毒性,与铂类联用时逆转顺铂耐药。
  • APCS-540显著减少癌细胞侵袭。
  • 接受APCS-540治疗的小鼠较对照组小鼠生存率显著提高66%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the anti-tumor effect of a newly-developed dual inhibitor (APCS-540) of glycogen synthase kinase 3 beta (GSK3B) and histone deacetylases (HDACs) in ovarian cancer cells. METHODS: The effects of APCS-540 on cancer cell proliferation, migration, invasion and cancer stemness were investigated in vitro in human (KURAMOCHI, OVCA420, OVSAHO) and mouse (BR-Luc, ID8, MOSE-HRas-Myc) ovarian cancer cells. Cisplatin-sensitive (A2780) and cisplatin-resistant (A2780cis) cell lines were used to evaluate APCS-540's effect on chemoresistance. The immunocompetent syngeneic mouse model BR-Luc was used to test the effect of APCS-540 on ovarian cancer progression and survival. RESULTS: APCS-540 showed significant anti-tumor effects in vitro in both human and mouse ovarian cancer cells. Importantly, APCS-540 demonstrated marked cytotoxicity against cisplatin-resistant cancer cells and reversed cisplatin-resistance when used in combination with platinum. APCS-540 significantly decreased cancer cell invasion. A significant 66% increase in survival was observed in mice treated with APCS-540 compared to control mice. CONCLUSION: Dual inhibition of GSK3B and HDACs via APCS-540 showed potent anti-tumor activity in vitro and in vivo, suggesting that APCS-540 may provide a novel treatment option for ovarian cancer, including the platinum-resistant disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Taylan E, Zayou F, Murali R, et al. Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model. Gynecol Oncol. 2020. PMID: 32698955. doi:10.1016/j.ygyno.2020.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。